Proactive Investors - Run By Investors For Investors

Flexion Therapeutics sees revenue jump 36% in preliminary 4Q results

The biotech expects revenue from Zilretta, its osteoarthritis injectable treatment, to be between $65 million and $80 million
Hands holding a knee in pain
The pharmaceutical company specializes in treating musculoskeletal conditions

Flexion Therapeutics Inc (NASDAQ:FLXNreported a double-digit revenue boost in its preliminary fourth-quarter results after the bell Thursday, but the numbers still fell short of Wall Street expectations.

The biotech expects fourth-quarter revenue to total $9.5 million, a 36% jump compared with this year's third quarter, while full-year revenue is expected to be around $22.5 million.

READ: Biotech CEOs see Bristol-Myers' $74B acquisition of Celgene as a win

The preliminary guidance fell below analyst estimates of fourth-quarter revenue of $10.2 million and full-year revenue of $23.1 million, as per a MarketWatch report.

Shares of the Massachusetts-based company dipped more than 5% to $11.70 in Thursday after-hours trading.

The pharmaceutical company specializes in the treatment of musculoskeletal conditions, including osteoarthritis.

Its product, Zilretta, is an injection intended to manage osteoarthritis pain in the knee.

Each year, roughly five million people in the U.S. receive intra-articular injections for osteoarthritis knee pain, and we believe ZILRETTA will play an increasingly significant role in the treatment paradigm for this large and growing patient population,” said CEO Michael Clayman.

Flexion’s initial product revenue guidance for Zilretta is between $65 million to $80 million, below analyst expectations of $97.8 million.

“We now enter 2019 with a product-specific J code (J3304), which we believe will be a key driver of continued ramp, as it provides prescribers with a well-known and clearly defined reimbursement mechanism that is utilized by both Medicare and private payers,” noted Clayman.

The company announced earlier this week it enrolled its first patient in a Phase 3 clinical trial of Zilretta.


--Contact Lenore Fedow at [email protected]

--Follow her on Twitter@LenoreMariee


View full FLXN profile View Profile

Flexion Therapeutics Incorporated Timeline

Related Articles

June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use